Circulating and hepatic fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma

MedGenMed Medscape General Medicine

Volumn 10, Issue 6, 2008, Pages

  El Bassiouny, Azza E I ^a   El Bassiouni, Nora E I ^b   Nosseir, Mona M F ^c   Zoheiry, Mona M K ^a   El Ahwany, Eman G ^a   Salah, Faten ^a   Omran, Zeinab S O ^c   Ibrahim, Raafat A ^b  

^a Giza   (Egypt)

^b THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^c Imbaba   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; FAS ANTIBODY; FAS ANTIGEN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CANCER INCIDENCE; CHOLECYSTECTOMY; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; EGYPT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; VIRUS CARCINOGENESIS; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VIROLOGY;

ADULT; ANTIGENS, CD95; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 44849140124     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Barth H, Ulsenheimer A, Pape GR, Presentation of hepatitis C virus-like particles by human dendritic cells. Blood. 2005;105:3605-3614.
2. Shin JY, Hur W, Wang JS, et al. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med. 2005;37:138-145.
3. Schinoni MI, Parana R. Apoptosis and progression of hepatic fibrosis in liver diseases. Acta Gastroenterol Latinoam. 2006;36:211-217.
4. Fischer R, Baumert T, Blum HE. Hepatitis C virus.infection and apoptosis. World J Gastroenterol. 2007;13:4865-4872.
5. Suda T, Takashi T, Goldstein R, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178.
6. Griffith T, Brunter T, Fletcher S, Green D, Ferguson T. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
7. Lee SH, Kim SY, Lee YH, et al. Detection of soluble Fas mRNA using in situ reverse transcriptase-polymerase chain reaction. Lab Investig. 1998;78:453-459.
8. Lee WC, YU MC, Chen MF. Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. World J Surg. 2004;28:792-796.
9. Hayashi N, Mita E. Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol. 1997;12:S223-S226.
10. Casino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995;154:706-2713.
11. Ching J, Zhou T, Liu C, et al. Protection from Fas mediated appptosis by a soluble form of Fas molecule. Science. 1994;263:1759-1762.
12. Knipping E, Depatin KM, Stricker K, Hellig B, Eder A, Krammer PH. Identification of soluble APO-1 in supernatants of, human B- and T-cell lines and increased serum levels in B- and T-cell leukaemias. Blood. 1995;85:1562-1569.
13. Midis GP, Shen Y, Owen LB. Elevated soluble Fas (sFas) levels in non haematopoietic human malignancy. Cancer Res. 1996;56:3870-3874.
14. Osario LM, Angular M, De Santiago A, Hachiya T, Mellstedt H, Jondal M. Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol. 2001;66:342-346.
15. Kiyici M, Gurel S, Budak F, et al. Fas antigen (CD95) expression and apoptosis in hepatocytes of patients with chronic viral hepatitis. Euro J Gastroenterol Hepatol. 2003;15:1079-1084.
16. Wu JX. Apoptosis and angiogenesis: tow promising tumor markers in breast cancer. Anticancer Res. 1996;16:2233-2240.
17. Pan G, Vickers SM, Pickens A, et al. Apoptosis and tumorigenesis in human cholangiocarcinoma Cells: Involvement of Fas/APO-1 (CD95) and Calmoulin. Am J Pathol. 1999;155:193-203.
18. El Bassiouny AEI, Zoheiry MMK, Nosseir MMF, El-Ahwany EG, El-Bassiouni NEI. Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. MedGenMed. 2007;9(3):45. Published online 2007 August 28.
19. Scheuer PJ. Chronic hepatitis. In: Scheuer PJ, Lefkowitch JH, eds. Liver Biopsy Interpretation. 6th ed. London: Saunders, Elsevier Science, Inc. 2003:151-172.
20. Ishak KG, Anthony PP, Sobin LH. Histological typing of tumors of the liver. In: World Health Organization. International Histological Classification of Tumors, 2nd ed, Berlin: Springer-Vedag; 1994: 91-118.
21. Hiramatsu N, Hayashi N, Katayama K, et al. Immunchistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 1993;46:1354-1359.
22. Chen NL, Bai L, Deng T. Study on pathway of apoptosis in chronic liver disease. Zhonghua Chuanranbing Zazhi. 2003;21:122-124.
23. Rosai J. Gastrointestinal tract, liver. In: Rosai and Ackerman's Surgical Pathology. 9th ed. Volume 2. Chapter 13. London: Saunders, Elsevier Science. 2004: 776-856.
24. Nagai H, Miyaki D, Matsui T, et al. Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Cancer Chernother Pharmacol. 2007; (Epub ahead of print).
25. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths. Hepatology. 2006;43:S31-S44.
26. Owen-Schaub LB, Angelo LS, Radinesky R, Ware CF, Gesner DP. Should Fas/ APO-1 in tumor cells a potential regulator of apoptosis? Cancer Lett. 1995;94:1-8.
27. Kakiuchi Y, Yuki N, Igoda K, Sugiyasu Y, Kaneko A, Kato M. Circulating soluble Fas levels in patients with hepatitis C virus infection and interferon therapy. J Gastroenterol. 2004;39:1189-1195.
28. Yoneyama K, Goto T, Miura K, et al. The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virus. Hepatol Res. 2002;24:327-337.
29. Seichima. M, Takemura M. Saito K, Ando K, Noma A. Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis. J Hepatol. 1997;27:424-427.
30. Jodo S, Kobayashi S, Nakajima Y, et al: Elevated serum levels of soluble Fas/ Apo-1 (Cdas) in patients with hepatocellular carcinoma. Clin Exp Immunol. 1998;112:166-171.
31. Ozaslan E, Kilioaeslan A, Simsek H, Fater G, Kirazli S. Elevated serum soluble Fas levels in the various stages of hepatitis C virus-induced liver disease. J Inter Med Res. 2003;31:384a-391.
32. Mochizulki K, Hayashi N, Hiramatsu N, et al. Fas antigen expression in liver tissue of patients with chronic hepatitis B. J Hepatol. 1996;24:1-7.
33. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of Apo-1: a new member of the nerve growth factor/tumor necrosis factor receptor superfamily in normal and neoplastic cells. Lab Invest. 1993;69:415-429.
34. Tsugeno H, Yamada G, Takatani M, et al. Immunohistochemical study of Fas antigen in human liver tissues. Hepatology. 1994;202:145A
35. Seino KI, Kayagaki N, Fukao K, Okumura K, Yagita H. Contribution of Fas ligand to T-cell mediated hepatic injury in mice. Gastroenterology. 1997;113:1315-1322.
36. Hirashima N, Matsumoto Y, Ohono T, Kimura Y, Hasegawa I, Ueda R. Hepatic Fas protein expression might be a predictive factor for hepatocellular carcinoma development in patient with chronic hepatitis C undergoing interferon tberapy. J Clin Gastroenterol. 2002;34:263-267.
37. Moriya K, Fujii H, Shintani Y, et al. Hepatitis C core protein induces, hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065-1071.
38. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatic C virus core protein. Virology. 1996;226:176-182.
39. Akazawa Y, Gores GJ. Death receptor mediated liver injury. Semin Liver Dis. 2007;27:327-338.
40. Zhang L, Wang X, Zheng W, Shi M. The effects of interleukin-10 on the expression of Fas and Fasl in rat hepatic stellate cells. Med Chem. 2006;2:611-616.
41. Kamegaya Y, Hiasa Y, Zukerberg L, et al. Hepatitig C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology. 2005;41:660-667.
42. Fabregat I, Roncero C, Fernandz M. Survival and apoptosis: a deregulated balance in liver cancer. Liver Int. 2007;27:155-162.
43. El Bassiouny A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, El-Bassiouni N. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. APMIS. 2006;114:420-427.
44. Mohammedein A, Yousif-Kadaru AG, Ahmed SA: A carboxy prothrombin (PIVKA II) as a tumor marker for hepatocellular carcinoma and other liver diseases. East Afr Med J. 1995;72:584-587.
45. Garcia CD, Guzman de la FJ, Munoz ELE: Primary liver cancer. Its epidemiological, clinical and biochemical characteristics. Rev Gastroenterol Mex. 1994;59:17-22.